Evidence map›Paper›PMID 41426235›Full record

ReviewTherapeutics and clinical risk management2025

Modulating Metabolic Health and Physiological Functions: Advances in Dietary Interventions Targeting Gut Microbiota.

Syed Arman Rabbani, Mohamed El-Tanani, Miodrag Janić, Andrej Janež, Yahia El Tanani, Eman Hajeer, Mohammad I Matalka, Manfredi Rizzo, Rakesh Kumar

Abstract readReview
In one paragraph

Review in Therapeutics and clinical risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Syed Arman RabbaniRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.ORCID 0000-0002-8454-8158
Mohamed El-TananiRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.ORCID 0000-0002-4735-5445
Miodrag JanićDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.ORCID 0000-0001-7073-8922
Andrej JanežDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Yahia El TananiRoyal Cornwall Hospital, NHS Trust, Treliske, Truro, UK.
Eman HajeerFaculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Mohammad I MatalkaDepartment of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Manfredi RizzoRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.ORCID 0000-0002-9549-8504
Rakesh KumarDepartment of Pharmacy, Jagannath University, Bahadurgarh, Haryana, 124507, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human gut possesses a highly complex and metabolically functional microbial community. This microbial ecosystem, often termed a "super-organism", plays a critical function in regulating the host's metabolic processes, including gut motility, energy absorption, appetite, glucose and lipid metabolism, as well as hepatic fat storage. These metabolic functions of the gut microbiota (GM) play a central role in maintaining host homeostasis and overall metabolic health. This review synthesizes findings from recent clinical and preclinical studies, focusing on the interactions between gut microbiota, metabolic functions, and dietary interventions, to provide an evidence-based overview of current knowledge and future perspectives. Evidence was compiled through a narrative review of studies indexed in PubMed, Scopus, Web of Science, and Google Scholar using prespecified keywords related to gut microbiota, metabolic syndrome, diet, and dysbiosis.Recent advancements in nutritional science and microbiology have highlighted the substantial relation between the GM and multiple pathological conditions, including metabolic syndrome (MetS). A plethora of studies predict that disruptions in the GM, known as dysbiosis, may influence the progression of diabetes, obesity, and cardiovascular diseases (CVDs). Notably, elucidating the contributions of the GM in the pathogenesis of MetS could offer promising avenues for therapeutic interventions. Herein, we review the physiological and metabolic functions of the GM and its connection to MetS pathogenesis, while also highlighting the potential molecular mechanisms underlying these observed associations. Furthermore, we discuss the influence of different dietary approaches on MetS and the impact of nutritional therapeutic strategies to support the development of beneficial gut bacteria and alleviate dysbiosis. By integrating insights from both clinical and preclinical research, this study provides a comprehensive overview of how GM modulation can support metabolic health. The possibility of tailoring nutritional interventions based on individual microbiota profiles represents a promising frontier for personalized and effective approaches to improve metabolic health.

Indexed as

cardiovascular diseasesdiabetesdietary patternsgut microbiotametabolic syndromeobesity

Identifiers

PMID41426235
PMCPMC12713056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.